All News
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
Read Article
Itaconate - A Potential New Immunosuppressive
EurekAlert!
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
Read Article
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read Article
Smoking and SLE
Smoking increases SLE activity
Smoking decreases HCQ efficacy
Skin response on HCQ down 50% in smokers 🚬
@Lupusreference #RNL2023 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
TULIP trials in lupus, disease outcomes and others, by Richard Furie #RNL2023 @RheumNow https://t.co/uUQOxUIzJN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Furie: #RNL2023
Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease
Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature
@RheumNow https://t.co/30oFRwwuTG
Eric Dein ericdeinmd ( View Tweet)
✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023
@RheumNow ⬇️ https://t.co/E2xdv3ODG6
Laurent ARNAUD Lupusreference ( View Tweet)
SRI Responders more likely able to reduce prednisone and far
Serological improvement
SF-36
Fatigue
by Richard Furie #RNL2023 @RheumNow https://t.co/ilsyOXw7nA
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Compliance is always an issue, by Richard Furie #RNL2023 @RheumNow .
Plaquenil level were below target. Adherence is always something we need to work on. https://t.co/hMgL9kY0rZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Ken Kalunian on Lupus nephritis
Don't forget about ACEi/ARB therapy for SLE pts with renal involvement
- can control BP
- reduce Urine proteinuria
- decrease risk of active renal disease
#RNL2023 @RheumNow https://t.co/hLBqjELqW2
Robert B Chao, MD doctorRBC ( View Tweet)
UPCR< 500 mg is the best predictor of a renal outcome in lupus nephritis. Multiple creatinine testing, Ken Kalunian #RNL2023 @RheumNow https://t.co/96PlXgqOfK
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Belimumab in Active lupus nephritis , Ken Kalunian #RNL2023 @RheumNow https://t.co/VZkmK8Iny7
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2023 Year in Review
@andreafava: urinary biomarkers in lupus nephritis
CD163, IL-16, CD206 decrease at 3 months.
Urinary biomarkers predict 1 year proteinuric response, esp in prolif LN.
Liquid biopsy as way to monitor instead of serial biopsies
@RheumNow https://t.co/baZt57Qjne
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Year in Review
HCQ levels in SLE
>500 ng/mL = 19x higher adherence
>750 ng/mL 67% lower odds of adherence
Higher levels with CKD
I use HCQ levels in all patients for monitoring at each visit
@RheumNow https://t.co/6yCefQdPU0
Eric Dein ericdeinmd ( View Tweet)
Should we be measuring HCQ levels?
- note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels
- adjust dose for pts with renal impairment
@RheumNow #RNL2023 https://t.co/JvaRJKJRPv
Robert B Chao, MD doctorRBC ( View Tweet)
Urinary biomarkers in lupus nephritis
@RheumNow and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology!
#RNL2023 https://t.co/l1gQgFhviI
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
✅ RheumNow Live 2023
#RNL2023 @RheumNow
Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq
Laurent ARNAUD Lupusreference ( View Tweet)
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS
Links:
Dr. John Cush RheumNow ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/sax8iHuljb https://t.co/71zqAzZViV
Links:
Dr. John Cush RheumNow ( View Tweet)
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM
Links:
Dr. John Cush RheumNow ( View Tweet)
